Telo Genomics Corp. (TDSGF)
USD 0.08
(14.29%)
USD 0.08
(14.29%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.62 Million | -1.79 Million | -1.1 Million | -1.11 Million | -327.83 Thousand | -3.2 Million |
| Net Income | -2.82 Million | -2.11 Million | -1.06 Million | -1.24 Million | -1.07 Million | -4.69 Million |
| Depreciation & Amortization | 33.11 Thousand | 56.95 Thousand | 62.22 Thousand | 64.71 Thousand | 82.9 Thousand | 124.32 Thousand |
| Deferred income taxes | -252.18 Thousand | -206.56 Thousand | -3750.00 | - | - | 102.26 Thousand |
| Stock-based compensation | 160.16 Thousand | 151.4 Thousand | 141.55 Thousand | 359.5 Thousand | 43.35 Thousand | 58.69 Thousand |
| Change in working capital | -2069.00 | 107.09 Thousand | -51.11 Thousand | -206.38 Thousand | 320.09 Thousand | 1.22 Million |
| Other non-cash items | 252.18 Thousand | 206.56 Thousand | -183.48 Thousand | -95.69 Thousand | 300 Thousand | -21.35 Thousand |
| Investing Cash Flow | -69.06 Thousand | -25.19 Thousand | -9310.00 | -8671.00 | - | -22.01 Thousand |
| Investments in PPE | -69.06 Thousand | -25.19 Thousand | -9310.00 | -8671.00 | - | -23.16 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -69.06 Thousand | - | - | -8.67 | - | 1148.00 |
| Financing Cash Flow | 2.67 Million | 876.65 | 3.82 Million | 2.02 Million | 280 Thousand | 2.09 Million |
| Debt repayment | -7500.00 | - | -15 Thousand | -350 Thousand | -280 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 2.83 Million | 876.64 Thousand | 2.09 Million | 1.73 Million | - | 2.12 Million |
| Other Financing Activities | -147.47 Thousand | 876.65 | 1.75 Million | 644.22 Thousand | 560 Thousand | -27.27 Thousand |
| Accounts receivables | -25.78 Thousand | 58.75 Thousand | -47.46 Thousand | -12.66 Thousand | 3932.00 | 292.01 Thousand |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | 23.71 Thousand | 48.34 Thousand | -3650.00 | -193.72 Thousand | 316.16 Thousand | 932.23 Thousand |
| Cash at beginning of period | 2.69 Million | 3.63 Million | 920.98 Thousand | 19.49 Thousand | 67.33 Thousand | 1.2 Million |
| Cash at end of period | 2.67 Million | 2.69 Million | 3.63 Million | 920.98 Thousand | 19.49 Thousand | 67.33 Thousand |
| Capital Expenditure | -69.06 Thousand | -25.19 Thousand | -9310.00 | -8671.00 | - | -23.16 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -19.71 Thousand | -943.53 Thousand | 2.71 Million | 901.48 Thousand | -47.83 Thousand | -1.13 Million |
| Free Cash Flow | -2.69 Million | -1.82 Million | -1.11 Million | -1.12 Million | -327.83 Thousand | -3.22 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -606.06 Thousand | -835.14 Thousand | -672.54 Thousand | -854.87 Thousand | -2.82 Million | -710.88 Thousand |
| Depreciation & Amortization | 9869.00 | 10.54 Thousand | 10.31 Thousand | 10.17 Thousand | 33.11 Thousand | 9004.00 |
| Deferred income taxes | - | -89.46 Thousand | -61.34 Thousand | -89.84 Thousand | -252.18 Thousand | -67.85 Thousand |
| Stock-based compensation | - | 60.75 Thousand | 42.07 Thousand | 41.61 Thousand | 160.16 Thousand | 42.48 Thousand |
| Change in working capital | 24.42 Thousand | 79.62 Thousand | -70.21 Thousand | 130.85 Thousand | -2069.00 | -5447.00 |
| Other non-cash items | -29.56 Thousand | 91.05 Thousand | 61.34 Thousand | 89.84 Thousand | 252.18 Thousand | 67.85 Thousand |
| Investing Cash Flow | - | - | -2800.00 | -1009.00 | -69.06 Thousand | -27.98 Thousand |
| Investments in PPE | - | - | -2800.00 | -1009.00 | -69.06 Thousand | -27.98 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -22.5 Thousand | - | -2282.00 | 2.61 Million | 2.67 Million | - |
| Debt repayment | - | - | - | - | -7500.00 | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | -2282.00 | 2282.00 | -2282.00 | 2.83 Million | 2.83 Million | - |
| Other Financing Activities | -20.21 Thousand | -2282.00 | -2282.00 | -214.97 Thousand | -147.47 Thousand | - |
| Accounts receivables | 39.3 Thousand | -7621.00 | 1349.00 | -27.88 Thousand | -25.78 Thousand | -7356.00 |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | -14.87 Thousand | 87.24 Thousand | -71.56 Thousand | 158.73 Thousand | 23.71 Thousand | 1909.00 |
| Cash at beginning of period | 1.29 Million | 1.97 Million | 2.67 Million | 727.57 Thousand | 2.69 Million | 1.42 Million |
| Cash at end of period | 690.88 Thousand | 1.29 Million | 1.97 Million | 2.67 Million | 2.67 Million | 727.57 Thousand |
| Capital Expenditure | - | - | -2800.00 | -1009.00 | -69.06 Thousand | -27.98 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -604.27 Thousand | -682.62 Thousand | -695.46 Thousand | 1.94 Million | -19.71 Thousand | -692.82 Thousand |
| Free Cash Flow | -581.77 Thousand | -682.62 Thousand | -693.18 Thousand | -673.23 Thousand | -2.69 Million | -692.82 Thousand |
062040
2437
VYNE
SLI
ARKAF
3943